Jefferies Reiterates Buy Rating on Amgen (AMGN)

Jefferies analyst Michael Yee reiterated a Buy rating and $375.00 price target on Amgen (NASDAQ: AMGN).

The analyst commented: "AMGN will report Phase III OX40 data in atopic derm in H2/24 (CT primary completion July-Aug). This an under the radar catalyst given the focus around obesity AMG133 data at YE but OX40 could be a $1-2B oppty and look competitive to Dupixent and given unique MoA may be more convenient and particularly attractive in prior Dupi pts. We think Phase III looks good and could be another catalyst. *SEE slides inside including comments on SNY OX40 data H1/26."

For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.

Shares of Amgen closed at $310.88 yesterday.

You May Also Be Interested In